Temozolomide: a novel treatment for pituitary carcinoma
| Autor: | William H. Yong, Anthony P. Heaney, Menahem M Maya, Stephen Lim, Hrayr Shahinian |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Gastroenterology Tumour tissue Microprolactinoma Internal medicine Temozolomide medicine Humans Combined Modality Therapy Pituitary Neoplasms Antineoplastic Agents Alkylating Aged Presyncope medicine.diagnostic_test business.industry Carcinoma Magnetic resonance imaging medicine.disease Magnetic Resonance Imaging Bromocriptine Dacarbazine Treatment Outcome Oncology Pituitary carcinoma business medicine.drug |
| Zdroj: | The Lancet Oncology. 7:518-520 |
| ISSN: | 1470-2045 |
| DOI: | 10.1016/s1470-2045(06)70728-8 |
| Popis: | Pituitary carcinoma is tumour tissue that is not contiguous with the pituitary tissues or is found in other extracranial sites. The disorder is rare (accounting for about 0·1% of pituitary tumours), rapidly progressive, and largely unresponsive to current combination treatment of surgery, radiation, and systemic chemotherapy. 2,3 Consequently, most patients die within 1 year of diagnosis. Here, we report a case of pituitary carcinoma treated with temozolomide. In June, 1997, a 72-year-old man with known microprolactinoma, successfully controlled with D2-agonist treatment (bromocriptine) for 7 years, presented with sudden headache and presyncope. His serum prolactin was very high at 2×10 3 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|